SV 101
Alternative Names: SV-101Latest Information Update: 14 Jun 2024
Price :
$50 *
At a glance
- Originator Syncromune
- Developer Syncromune; Williams Cancer Institute
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Breast cancer; Non-small cell lung cancer
Most Recent Events
- 01 Feb 2023 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease) in Mexico (Intratumoural) (NCT05544240) (Syncromune pipeline, June 2024)
- 16 Sep 2022 Phase-I clinical trials in Brest cancer (Metastatic disease, Late-stage disease) in Mexico (Intratumoural) (NCT05544240)